GenSight appoints Mohamed Genead as CMO

GenSight announced that it has appointed Mohamed Genead as Chief medical Officer, effective from May 1, 2017. He will be responsible for setting strategy for and execution of global clinical development programs, management of the Company’s medical affairs, clinical operations and biostatistics departments. He will be part of the Executive Committee and will report directly to Bernard Gilly, PhD, CEO of GenSight. Dr. Genead will be based on the East Coast of the US.

Mohamed Genead has more than 15 years of experience, including his most recent role as VP & Global Therapeutic Area Head for Ophthalmology/Retina Gene Therapy at Biogen. Prior to Biogen, Dr. Genead served eight years at Allergan as the Executive Medical Director, Global Clinical Development for the Ophthalmology/Retina Therapeutic Area. Before this, he was the Vice President & Global Head of Clinical Development at Allegro. Dr. Genead is a board member of several ophthalmic organizations, and he has authored numerous peerreviewed papers across his career.

GenSight CEO, Bernard Gilly said that Dr. Genead brings a wealth of gene therapy and retina expertise to the GenSight Biologics team. They look forward to his contributions as they complete their two ongoing pivotal Phase III trials of GS010 for Leber’s Hereditary Optic Neuropathy and prepare to initiate clinical development of GS030 for retinitis pigmentosa. His leadership in the field of ophthalmic drug development will be instrumental as they continue to progress their innovative pipeline of therapies to address sight-threatening diseases.